Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness of Momordica Charantia Extract Compared to the Standard Antimalarial Drug Combination Dihydroartemisinin Piperaquine-primaquine in Patients With Uncomplicated Falciparum Malaria, in Sumba Barat Daya District of Indonesia

NCT05829187 is registered in ClinicalTrials.gov with Syamsudin Abdillah,Ph.D, Pharm D as lead sponsor.

NCT NCT05829187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05829187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness of Momordica Charantia Extract Compared to the Standard Antimalarial Drug Combination Dihydroartemisinin Piperaquine-primaquine in Patients With Uncomplicated Falciparum Malaria, in Sumba Barat Daya District of Indonesia
Lead sponsor
Syamsudin Abdillah,Ph.D, Pharm D
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2022
Completion date
December 31, 2022
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

uncomplicated plasmodium falciparum